胰腺癌新辅助化疗后生化、影像或病理反应评估孰优
该单中心回顾性研究纳入2011至2022年225例接受新辅助治疗后切除的胰腺导管腺癌患者,比较生化(CA19-9)、影像(肿瘤直径)和病理(肿瘤消退分级)反应与总生存的关系。CA19-9下降>50%与总生存改善相关(32 vs 24个月,P=0.0028),但主要病理反应和影像反应未显示独立关联;生化与主要病理双重反应者总生存最长(40个月,P=0.0086)。
要点
- CA19-9下降>50%与总生存改善相关,单独病理或影像反应不足以预测生存
- 生化与主要病理双重反应者总生存最长,但仅9%患者达到
- 全身化疗后加新辅助放疗者双重反应比例更高(45% vs 11%)
核心结论
- 单独CA19-9反应不足以识别胰腺癌切除后长期生存者
- CA19-9与主要病理反应共存可预测最优生存结局
研究设计与样本
- 单中心回顾性分析2011至2022年225例新辅助治疗后行胰腺切除术的胰腺导管腺癌患者
- 新辅助方案包括Folfirinox(70%)、吉西他滨+白蛋白紫杉醇(19%)和放疗(18%)
主要发现
- CA19-9下降>50%者总生存改善(32 vs 24个月,P=0.0028)
- 主要病理反应(肿瘤消退分级0-1)与总生存无显著关联(P=0.067)
- 影像学反应(肿瘤直径下降>30%)与总生存无显著关联(P=0.89)
- 生化与主要病理双重反应者(9%)总生存最长(40个月,P=0.0086)
- 全身化疗后加新辅助放疗者双重反应更常见(45% vs 11%,P<0.001)
临床怎么用
- 评估新辅助治疗反应时应同时关注CA19-9和病理反应,而非单独依赖某一指标
- CA19-9下降>50%可作为生存获益的参考指标
- 全身化疗后加放疗可能提高双重反应比例,但需进一步验证
局限性
- 单中心回顾性研究,样本量有限
- 新辅助方案异质,包含化疗和放疗
- 双重反应亚组仅占9%,结论需外部验证
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the optimal method of assessing response to neoadjuvant therapy (NAT) in patients with operable pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: PDAC response to NAT is measured with biochemical, radiographic, and pathologic parameters, which can often be discordant with each other. METHODS: Patients with PDAC undergoing resection after NAT at a single institution were retrospectively analyzed. Tumor response was assessed using pre/post-NAT carbohydrate antigen 19-9 (CA19-9) levels, radiographic decrease in tumor diameter, and pathologic tumor regression grade. The association of these factors with overall survival (OS) was compared using Kaplan-Meier, Cox regression, and recursive partitioning analysis, a machine learning technique that can validate prediction models for complex hierarchical relationships. RESULTS: From 2011 to 2022, 225 patients underwent pancreatectomy after NAT (Folfirinox, 70%; gemcitabine + nab-paclitaxel, 19%; radiation, 18%). Almost half required vascular resection (portal vein, 39%; celiac axis 8%). Improved OS was observed after CA19-9 decrease >50% (32 vs 24 months, P = 0.0028), but not after major pathologic (tumor regression grade: 0-1, P = 0.067) or radiographic response (tumor diameter decrease >30%, P = 0.89). However, recursive partitioning analysis identified that the coexistence of biochemical and major pathologic response (achieved in 9% of patients) was associated with the longest OS (40 months, P = 0.0086). This optimal dual response combination was more commonly observed after neoadjuvant radiotherapy was used after systemic chemotherapy (45% vs 11%, P < 0.001). CONCLUSIONS: CA19-9 response to NAT alone is not enough to identify long-term postresection PDAC survivors. The coexistence of CA19-9 and major pathologic response was predictive of the most optimal survival outcome.
引用
- Ahmad MU, Javadi CS, Chang JD, et al. Biochemical, Radiographic, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? Ann Surg. 2024. PMID: 39676639. doi:10.1097/SLA.0000000000006609
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。